Lurex Bio, Inc., a biotechnology company pioneering next-generation immunotherapy platforms, today announced the filing of multiple U.S. provisional patents to protect its proprietary immune-signal and vesicle-based targeting systems. “These filings represent the company’s first step toward international protection under the Patent Cooperation Treaty (PCT) and mark a defining milestone in Lurex Bio’s evolution,” said Dr. Fred McCall-Perez, Chief Executive Officer of Lurex Bio.